Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Jazz Pharmaceuticals, Inc.

Oncology Briefings™: The Advent of Novel Treatment Approaches for SCLC

Release Date: June 29, 2020
Expiration Date: June 29, 2021

Activity Overview

This online activity is designed to provide a concise and focused overview on an important clinical topic, and includes information on standards of care, emerging therapeutic regimens, new approaches for optimal patient selection, and investigational therapies for small cell lung cancer (SCLC). The engaging, multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Jazz Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational initiative is directed toward medical oncologists who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other health care professionals interested in the treatment of lung cancer will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Assess the role of emerging treatment approaches on standards of care for patients with SCLC
  • Explain novel techniques for optimizing treatment selection in patients with SCLC
  • Outline information regarding ongoing and planned trials assessing efficacy and safety of current and emerging approaches for the treatment of SCLC

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Benjamin P. Levy, MD
Benjamin P. Levy, MD
Associate Professor, Johns Hopkins School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center, Sibley
Memorial Hospital
Washington, DC

Disclosures: Consultant: AstraZeneca, Pfizer, Eli Lilly, Genentech, Novartis, Takeda, Guardant.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By